Form 4: 10x Genomics CEO Serge Saxonov Reports Gift of 1,000 Shares and Trust Transfers

10x Genomics, Inc. CEO and Director Serge Saxonov filed a Form 4 detailing a gift of 1,000 Class A Common Stock shares and outlining his direct and indirect beneficial ownership, including recent transfers to family trusts.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), reported a disposition of 1,000 shares of Class A Common Stock as a gift.
• The transaction occurred on June 9, 2025, with a reported price of $0 per share.
• Following this transaction, Mr. Saxonov directly beneficially owns 955,240 shares of Class A Common Stock.
• He also holds indirect beneficial ownership of 361,102 shares through various trusts where he serves as trustee, including 27 shares via the Andromeda Trust, 89,825 shares via the Sirius Trust, 213,250 shares via the Y/S Descendants' Trust, and 58,000 shares via the Y/S Pot Trust.
• The reported direct beneficial ownership reflects prior transfers made on June 5, 2025, where 88,955 shares were transferred to the Sirius Trust and 35,430 shares to the Y/S Pot Trust.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Form 4) detailing an insider stock transaction (a gift). It does not contain information that would typically indicate positive or negative sentiment regarding the company's performance or outlook, hence a neutral score.

Future Outlook

N/A

Industry Context

This filing is a routine disclosure of an insider transaction, common for executives and directors of publicly traded companies. It provides transparency regarding changes in beneficial ownership but does not inherently reflect broader industry trends or competitive positioning.

Related Party Transactions

• Serge Saxonov transferred shares to and holds indirect beneficial ownership through various trusts (Andromeda Trust, Sirius Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which he serves as trustee, indicating a controlled beneficial ownership structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding insider stock ownership changes, which is standard regulatory disclosure and generally has minimal direct impact on share price for a small gift.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction filing.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, SEC Form 4, Insider Transaction, Stock Gift, Beneficial Ownership, Class A Common Stock, Trust Transfers